Most importantly, preliminary in vitro studies indicated that DMAPE can also selectively eradicate CD34+ AML cells similar to PepE without apparent toxicity to normal bone marrow cells, making it a novel drug lead for CD34+ AML cell-targeted therapy [23]. This evidence concerns the gene CD34 and acute myeloid leukemia.